Figures
- FIGURE 1.
Omalizumab dosing table (European Union). Ig: immunoglobulin; Q4 weeks: total dose to be administered every 4 weeks; Q2 weeks: half of total dose to be administered every 2 weeks.
- FIGURE 2.
Clinical status (▒) and oral corticosteroid (OCS; ░) dose of the case-study patient over a period of time. The arrow indicates the start of omalizumab off-label treatment. #: end of the Investigation of Omalizumab in Severe Asthma Treatment (INNOVATE) trial; ¶: time-point at which exacerbations occurred.
Tables
- Table 1—
Using omalizumab in clinical practice
Therapeutic indication (EU) Omalizumab is indicated as add-on therapy to improve asthma control in adult and adolescent patients (≥12 yrs of age) with severe persistent allergic asthma who have the following characteristics: A positive skin test or in vitro reactivity to a perennial allergen Reduced lung function (FEV1 <80%) Frequent daytime symptoms or night-time awakenings Multiple documented severe asthma exacerbations Receiving daily high-dose ICS and a LABA Omalizumab treatment should only be considered for patients with convincing IgE-mediated asthma Treatment should be initiated by physicians experienced in the diagnosis and treatment of severe persistent asthma Evaluating response 16 weeks after commencing omalizumab therapy, patients should be assessed by their physician for treatment effectiveness before further injections are administered. The decision to continue omalizumab therapy should be based on whether a marked improvement in overall asthma control is achieved EU: European Union; FEV1: forced expiratory volume in one second; ICS: inhaled corticosteroids; LABA: long-acting β2-agonist; Ig: immunoglobulin.
Vol 16 Issue 104
Table of Contents
Which patients should be treated with anti-IgE?
